NCT02086604View on ClinicalTrials.gov

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 18, 2014

Primary Completion Date

June 9, 2017

Study Completion Date

January 12, 2022

Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
DRUG

Brentuximab vedotin

DRUG

Lenalidomide

Trial Locations (2)

43210

Ohio State University, James Cancer Hospital, Columbus

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Seagen Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02086604 - Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter